Myopia Progression With a Novel Extended Depth of Focus Contact Lens

Sponsor
Aller, Thomas A., OD (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03358862
Collaborator
Visioneering Technologies, Inc (Industry)
80
1
65.9
1.2

Study Details

Study Description

Brief Summary

Myopia has been increasing in prevalence and severity throughout the world over the last 30 years. Increasing levels of myopia are associated with increased frequencies and severity of various ocular pathologies, including cataracts, glaucoma, retinal detachments and other retinal pathologies and myopic maculopathy. Slowing myopia progression at a young age before the eye reaches excessive axial length may help to reduce the future risks of these ocular pathologies.

Conventional spectacles and contact lenses are prescribed correct myopia by moving the central focus of the eye for distance viewing from in front of the retina to on the retina centrally, or at the fovea. To varying degrees, these lenses allow the light to focus behind the retina, at varying peripheral retinal locations. These findings have led to efforts to design spectacle and contact lenses which correct peripheral hyperopic defocus, to reduce myopia progression.

The consensus theory for how both multifocal contact lenses and orthokeratology can control myopia progression is that they each can reduce, eliminate, or reverse relative peripheral hyperopic defocus. Existing published studies on the use of multifocal contact lenses to control myopia in humans have utilized lenses with the distance correction in the center with peripheral plus power to correct the peripheral blur. Until recently, there have been no daily disposable multifocal lenses in the US market with distance center designs.

The NaturalVue contact lens from Visioneering Technologies, Inc. is the first daily disposable distance center multifocal in the US. It has a novel extended depth of focus design where the distance correction is in the center of the optical zone, surrounded by a zone characterized by having a seamless, rapid transition from the distance power to a highly plus power at the edge of the optical zone.

This study will analyze the myopia progression of patients in the investigator's practice while wearing their habitual visual corrections for periods up to two years prior to being switched to NaturalVue contact lenses. They will then be followed for up to two years after beginning use of this novel lens design and the differences in their myopia progression after versus before this novel lens will be analyzed. Axial lengths will be measured with the IOLMaster after switching to NaturalVue, at six-month intervals and will be compared to axial lengths which have been collected with habitual corrections.

Condition or Disease Intervention/Treatment Phase
  • Device: NaturalVue Multifocal Contact Lens

Detailed Description

Myopia has been increasing in prevalence and severity throughout the world over the last 30 years. Increasing levels of myopia are associated with increased frequencies and severity of various ocular pathologies, including cataracts, glaucoma, retinal detachments and other retinal pathologies and myopic maculopathy. Slowing myopia progression at a young age before the eye reaches excessive axial length may help to reduce the future risks of these ocular pathologies.

Conventional spectacles and contact lenses are prescribed to correct myopia by moving the central focus of the eye for distance viewing from in front of the retina to on the retina centrally, or at the fovea. To varying degrees, these lenses allow the light to focus behind the retina, at varying peripheral retinal locations. These findings have led to efforts to design spectacle and contact lenses which correct peripheral blur to reduce myopia progression.

The consensus theory for how both multifocal contact lenses and orthokeratology can control myopia progression is that they each can reduce, eliminate, or reverse relative peripheral hyperopic defocus. Existing published studies on the use of multifocal contact lenses to control myopia in humans have utilized lenses with the distance correction in the center with peripheral plus power to correct the peripheral hyperopic defocus. Until recently, there have been no daily disposable multifocal lenses in the US market with distance center designs.

The NaturalVue contact lens from Visioneering Technologies, Inc. is the first daily disposable distance center multifocal in the US. It has a novel extended depth of focus design where the distance correction is in the center of the optical zone, surrounded by a zone with a seamless, rapid transition from the distance power to a highly plus power at the edge of the optical zone.

This study will analyze the myopia progression of patients in the investigator's practice while wearing their habitual visual corrections for periods up to two years prior to being switched to NaturalVue contact lenses. They will then be followed for up to two years after beginning use of this novel lens design and the differences in their myopia progression after NaturalVue versus before NaturalVue will be analyzed. Axial lengths will be measured with the IOLMaster after switching to NaturalVue, at six-month intervals and will be compared to axial lengths which have been collected with habitual corrections.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
80 participants
Observational Model:
Case-Only
Time Perspective:
Other
Official Title:
Myopia Progression in Children and Adolescents Before and After Use of a Novel Extended Depth of Focus Daily Disposable Soft Contact Lens
Actual Study Start Date :
Jan 1, 2017
Anticipated Primary Completion Date :
Jan 1, 2022
Anticipated Study Completion Date :
Jul 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Myopes

Children, adolescents and young adults with existing progressive myopia equal to or exceeding -0.50 D in the year prior to beginning the use of the NaturalVue contact lens.

Device: NaturalVue Multifocal Contact Lens
NaturalVue multifocal contact lenses are daily disposable, distance center, multifocals with a novel extended depth of focus optical design. Patients wearing their habitual corrections who opt to change to this new lens will have their myopia progression monitored for up to two years.

Outcome Measures

Primary Outcome Measures

  1. Refractive error changes [Data will be collected at baseline and at every six months.]

    Changes in myopia over time will be characterized by the spherical equivalent refractive error as measured by manifest subjective refraction.

  2. Axial length of the eye [Data will be collected at baseline and at every six months.]

    Changes in the axial length of the eye will be measured with the Zeiss IOLMaster

Secondary Outcome Measures

  1. Corneal curvature [Data will be collected at baseline and at every six months]

    Keratometry will be measured by the Zeiss IOLMaster

  2. Vitreous Chamber Depth [Data will be collected at baseline and at every six months.]

    Vitreous Chamber Depth will be derived from measures of the Anterior Chamber Depth and the axial length as measured by the Zeiss IOLMaster.

Eligibility Criteria

Criteria

Ages Eligible for Study:
5 Years to 25 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Myopic refractive error

  • Astigmatism less than -2.50 D

  • Evidence from clinical record of myopia progression equal to or greater than -0.50 D in at least one eye since the prior examination

  • Ability to see 20/30 or better in the worse eye and 20/25 or better binocularly after one week adaptation

  • Ability to properly insert, remove and care for study lens

Exclusion Criteria:
  • Moderate to severe allergic conjunctivitis

  • Moderate to severe dry eyes

  • Keratoconus or other related corneal irregularity

  • Strabismus

  • Amblyopia

  • Nystagmus

Contacts and Locations

Locations

Site City State Country Postal Code
1 Dr. Thomas Aller Optometrist, Inc. San Bruno California United States 94066

Sponsors and Collaborators

  • Aller, Thomas A., OD
  • Visioneering Technologies, Inc

Investigators

  • Principal Investigator: Thomas A Aller, OD, Independent

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Thomas A. Aller, OD, Principal Investigator, Aller, Thomas A., OD
ClinicalTrials.gov Identifier:
NCT03358862
Other Study ID Numbers:
  • SI-09-37
First Posted:
Dec 2, 2017
Last Update Posted:
Jan 12, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Thomas A. Aller, OD, Principal Investigator, Aller, Thomas A., OD
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 12, 2021